User profiles for Maria Bjerke
 | Maria BjerkeAss prof. University of Antwerp, Vrije Universiteit Brussel Verified email at uzbrussel.be Cited by 7892 |
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
…, U Andreasson, A Öhrfelt, E Portelius, M Bjerke… - The Lancet …, 2016 - thelancet.com
Background Alzheimer's disease biomarkers are important for early diagnosis in routine
clinical practice and research. Three core CSF biomarkers for the diagnosis of Alzheimer's …
clinical practice and research. Three core CSF biomarkers for the diagnosis of Alzheimer's …
Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis
Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …
number of neurological conditions compared with healthy controls (HC) and is a candidate …
[HTML][HTML] Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid
M Bjerke, E Portelius, L Minthon, A Wallin… - International journal of …, 2010 - hindawi.com
Background. Patients afflicted with Alzheimer's disease (AD) exhibit a decrease in the
cerebrospinal fluid (CSF) concentration of the 42 amino acid form of -amyloid ( ). However, a high …
cerebrospinal fluid (CSF) concentration of the 42 amino acid form of -amyloid ( ). However, a high …
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
A Thorsell, M Bjerke, J Gobom, E Brunhage… - Brain research, 2010 - Elsevier
Synaptic pathology occurs early in Alzheimer's disease (AD) development, and cerebrospinal
fluid biomarkers for synaptic damage may be altered early in the disease process. In the …
fluid biomarkers for synaptic damage may be altered early in the disease process. In the …
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the …
…, L van Waalwijk van Doorn, M Bjerke… - The world journal of …, 2018 - Taylor & Francis
In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers
of neurodegenerative dementias, enormous advancement has taken place in the field, …
of neurodegenerative dementias, enormous advancement has taken place in the field, …
Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia …
M Bjerke, H Zetterberg, Å Edman… - Journal of …, 2011 - content.iospress.com
Alzheimer's disease (AD) and vascular dementia (VaD) are intertwined by mixed dementia (MD)
harboring varying degrees of AD pathology in combination with cerebrovascular …
harboring varying degrees of AD pathology in combination with cerebrovascular …
[HTML][HTML] Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
…, SK Herukka, N Andreasen, I Baldeiras, M Bjerke… - Alzheimer's & …, 2017 - Elsevier
This article presents recommendations, based on the Grading of Recommendations, Assessment,
Development, and Evaluation method, for the clinical application of cerebrospinal fluid …
Development, and Evaluation method, for the clinical application of cerebrospinal fluid …
[HTML][HTML] Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF)
reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than …
reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than …
Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease
…, K Bossers, R Vandenberghe, A Wallin, M Bjerke… - Neurology, 2013 - AAN Enterprises
Objective: We evaluated microRNAs (miRNAs) as potential biomarkers for Alzheimer disease
(AD) by analyzing the expression level of miRNAs in CSF of patients with AD dementia …
(AD) by analyzing the expression level of miRNAs in CSF of patients with AD dementia …
[HTML][HTML] Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment
…, N Andreasen, I Baldeiras, M Bjerke… - Alzheimer's & …, 2017 - Elsevier
This article presents recommendations, based on the Grading of Recommendations, Assessment,
Development, and Evaluation method, for the clinical application of cerebrospinal fluid …
Development, and Evaluation method, for the clinical application of cerebrospinal fluid …